This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): epoetin alfa
Description: Epogen is a recombinant human erythropoeitin (epo) formulation indicated for stimulating red blood cell production in patients with anemia associated with chronic renal (kidney) failure, HIV-infected patients with Zidovudine (AZT)-induced anemia, and chemotherapy-induced anemia, as well as for the reduction of allogenic blood transfusions in certain surgery patients.
Deal Structure: Epogen was developed by a joint venture between Amgen and Kirin Brewery. The joint venture licensed Amgen the rights to epogen outside of Japan and the Peoples Republic of China. Amgen pays Kirin a royalty on these sales. Kirin obtained the rights to market epoetin alfa in Japan and the PRC for all indications.
In 1985, Amgen granted Johnson and Johnson (J&J) a perpetual license to market epoetin alfa in the United States for all uses except dialysis and diagnostics. Amgen retained the rights to market epogen in the U.S. for the dialysis market and receives a royalty from J&J sales. J&J also has the rights to market epoetin alfa for all uses outside of the U.S., Japan, and China.
Partners: Kyowa Hakko Kirin Co., Ltd. Johnson & Johnson
Additional information available to subscribers only: